Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib

Giuseppe Cabibbo, Emanuela Rolle, Massimo De Giorgio, Chiara Genco, Tiziana Pressiani, Francesca Spada, Rodolfo Sacco

Research output: Contribution to journalArticle


Sorafenib (Nexavar®, Bayer), a multi-targeted tyrosine kinase inhibitor, was the first systemic agent that demonstrated a significant improvement in the overall survival in patients with advanced hepatocellular carcinoma and well-preserved liver function. This drug is now recommended in patients with advanced hepatocellular carcinoma as first-line therapy and for patients not suitable for locoregional treatment. This brief article, produced by a multidisciplinary panel including specialists in gastroenterology and oncology, provides an overview of the major issues related to systemic treatment of hepatocellular carcinoma with sorafenib, including staging and prognostic strategies, assessment of liver disease and its complications, and efficacy and safety of this molecule. Particular emphasis is given on how to improve tolerability of sorafenib in difficult-to-treat patients.

Original languageEnglish
Pages (from-to)1807-1816
Number of pages10
JournalExpert Review of Anticancer Therapy
Issue number12
Publication statusPublished - Dec 2011



  • cirrhosis
  • hepatocellular carcinoma
  • liver cancer
  • management
  • sorafenib
  • systemic therapy
  • treatment

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this